Authors: Storm Johnson (Future Science Group)
Phase III trials for the VLA1553 vaccine against chikungunya virus indicated promising results by inducing protective CHIKV neutralizing antibody titers within 28 days of the single-dose. VLA1553 is currently the only promising candidate in Phase III trials targeting long term protection against chikungunya.
French vaccine developer, Valneva, announced positive results from Phase III trials of their single-dose chikungunya vaccine VLA1533, which exceeded the US FDA 70% protection threshold, reaching levels of 98.5% seroprotection. As such, the program has been awarded Breakthrough Designation status by the FDA, holding promise for the world’s first single-dose vaccine providing long-term protection against chikungunya virus (CHIKV).